Introduction
============

Hepatocellular carcinoma (HCC) is one of the most frequent malignancies in the world. The estimate incidence of liver cancer ranked fourth and its mortality ranked third in People's Republic of China, 2015.[@b1-ott-9-5163] Currently, several genes have been identified to be related with the tumorigenesis and progression of HCC, but the molecular mechanisms of their functions and interactions have not been clearly studied. Therefore, it is urgent to find the potential function of these genes during the development of HCC.

MicroRNA (miRNA) is classified as endogenous noncoding RNA, repressing protein translation by binding to their target genes.[@b2-ott-9-5163] From nearly all biological processes, miRNA can exert the function as posttranscriptional regulation.[@b3-ott-9-5163] Aberrant expression of microRNA-198 (miR-198) has been found to be correlated to the carcinogenesis and disease progression of several classes of cancers, including lung adenocarcinoma,[@b4-ott-9-5163] esophageal cancer,[@b5-ott-9-5163] squamous cell carcinoma of tongue,[@b6-ott-9-5163] retinoblastoma,[@b7-ott-9-5163] pancreatic adenocarcinoma,[@b8-ott-9-5163] multiple myeloma,[@b9-ott-9-5163] colorectal cancer,[@b10-ott-9-5163] and prostate cancer.[@b11-ott-9-5163] However, there were only three research papers studying the expression of miR-198 in HCC. Varnholt et al first reported the lower expressed miR-198 in Caucasian patients with hepatitis C virus (HCV) related HCC.[@b12-ott-9-5163] Tan et al identified the suppressing role of miR-198 in HGF/c-MET pathway that influenced migration and invasion of HCC cells.[@b13-ott-9-5163] Elfimova et al found another pathway that was repressed by miR-198 in vitro which could negatively regulate cell growth and migration.[@b14-ott-9-5163] However, whether miR-198 is related to clinicopathological parameters has not been studied, there still remains a mystery regarding miR-198's role in the key processes of hepatocellular carcinogenesis.

Thus, in this study, we assessed the expression of miR-198 in tumor tissues of HCC patients with their paired noncancerous liver. In addition, the relationship of miR-198 with several clinicopathological parameters was also investigated. Moreover, we predicted the target genes of miR-198 via 14 miRNA databases and filtered in the natural language processing (NLP) to achieve the specific messenger RNAs (mRNA) profiles of miR-198 targets for HCC. Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway annotation were further undertaken to explore the function of these mRNAs. We attempted to pioneer the use of real-time reverse transcription quantitative polymerase chain reaction (RT-qPCR) and in silico method to clarify the potential molecular mechanism of miR-198, providing guidelines for the following research on miR-198 in HCC.

Materials and methods
=====================

Tissue samples
--------------

There were 95 cases of HCCs and their paired paraneoplastic liver formalin-fixed paraffin-embedded (FFPE) tissues included in this retrospective study. The age of the HCC patients ranged from 29 to 82 years old, with a mean age of 52 years. All the clinicopathological features are provided in [Table 1](#t1-ott-9-5163){ref-type="table"}. Adjacent noncancerous liver tissues were obtained from the location at least 2 cm away from the tumor node. The adjacent tissue was from the same HCC patient. We designed these paired sample groups in order to eliminate the individual difference. Tumor sizes of HCC ranged from 1 to 11 cm (mean size, 6.4 cm). All cases were from patients who were under initial hepatectomies without any treatment and they were randomly chosen from hepatectomy surgeries in the First Affiliated Hospital of Guangxi Medical University, People's Republic of China between March 2010 and December 2011. The research protocol was approved by the Ethical Committee of the First Affiliated Hospital of Guangxi Medical University. Written informed consent was signed by the patients for the treatment and sample usage in this study. All samples were diagnosed by three pathologists independently (Dian-zhong Luo, Zhen-bo Feng, Gang Chen).

RT-qPCR
-------

Total RNA including miRNA was extracted from tumor and nontumorous liver sections and the miRNeasy FFPE kit (QIAGEN, KJ Venlo, the Netherlands) was applied according to our previous reports.[@b15-ott-9-5163]--[@b17-ott-9-5163] RNA concentrations were measured by NanoDrop 2000 (Thermo Fisher Scientific, Wilmington, DE, USA). The OD260/OD280 ratio of the total mRNA (including miRNA) isolated from the FFPE tissues ranged from 1.84 to 2.06, and OD260/OD230 from 1.90 to 2.04. The PCR amplification efficiency of all the quantitative real-time PCR (RT-qPCR) reactions ranged from 91.0% to 95.2%. A combination of RUN6B and RUN48 was chosen as the house-keeping reference for detection of miR-198 expression. The primers of miR-198, as well as RNU6B and RNU48, were provided by TaqMan^®^ MicroRNA Assays (4427975, Applied Biosystems, Life Technologies, Grand Island, NY, USA). Sequence of miRNA and references in the paper were as follows: miR-198 (Applied Biosystems Cat No 4427975-000468): UCCCAAAUGUAGACAAAGCA; RNU6B (Applied Bio-systems Cat No 4427975-001093): CGCAAGGAUGACAC GCAAAUUCGUGAAGCGUUCCAUAUUUUU; RNU48 (Applied Biosystems Cat No 4427975-001006): GAUG ACCCCAGGUAACUCUGAGUGUGUCGCUGAUGCCA UCACCGCAGCGCUCUGACC. The reverse transcription was carried out with TaqMan^®^ MicroRNA Reverse Transcription Kit (4366596, Applied Biosystems, Life Technologies) in a total volume of 10 µL. Real-time qPCR for miRNA trial was performed with Applied Biosystems PCR7900. The normalization of miR-198 quantity in each sample was compared with its internal reference. At last, the formula 2^−Δcq^ was used to calculate the expression of miR-198 in this experiment.[@b15-ott-9-5163]

Potential target mRNAs of miR-198 in HCC
----------------------------------------

To achieve predicted target mRNAs of miR-198, 14 miRNA in silico databases were used in this study, including TargetScan, miRanda, RNAv22, miRWalk, miRTarBase, PicTar, TargetS, DIANA, miRDB, miRNAMap, PITA, TargetMiner, Human miRNA Targets, and PolymiRTS Database. More than 16,000 target mRNAs were predicted once in total. Only mRNAs that were simultaneously predicted by four or more than four databases were selected for subsequent study. Other validated genes targeted by miR-198 were also added to the study throughout literature review.

NLP analysis of liver cancer
----------------------------

To identify the specific genes that were abnormally expressed in HCC, we conducted a literature search in the PubMed and EMBASE with an attempt to cover all studies available in publication from January 1980 and May 2015 through the following strategy: (liver or hepat\*) and (cancer or carcinoma or tumor or neoplasm or malignan\* or carcinogenesis or tumorigenesis) and (resistance OR prognosis OR metastasis OR recurrence OR survival OR sorafenib OR bevacizumab) ("1980/01/01" \[PDAT\]: "2015/05/25" \[PDAT\]). We then identified all the genes and mRNAs that were associated with the key message, and used a biomedical tool -- entity recognizer (ABNER)[@b16-ott-9-5163] to add them to a list via gene mention tagging.[@b17-ott-9-5163]

Gene-enrichment and functional annotation analysis
--------------------------------------------------

To evaluate the function of the potential target mRNAs, we used the GO terms and KEGG pathway annotation for the miR-198 targets based on functional annotation summaries provided by DAVID (Database for Annotation, Visualization, and Integrated Discovery, <http://david.abcc.ncifcrf.gov/>).[@b18-ott-9-5163] The GO terms with a modified Fisher exact *P*-value \<0.01 and the pathways with *P*-value \<0.05 were chosen for the next analysis. The enrichment map of annotation analysis was drawn by software Cytoscape 3.3.0.[@b19-ott-9-5163]

Validation of the expression of some potential target genes based on The Cancer Genome Atlas (TCGA) dataset
-----------------------------------------------------------------------------------------------------------

To further study the potential role of miR-198, additional analyses were performed on the expression of some predicted genes randomly selected from one top pathway generated by the signaling pathway analysis. All gene expressions of 369 patients of liver HCC and 50 adjacent liver tissues were extracted and analyzed from the TCGA RNAseq profiles (<http://cancergenome.nih.gov>).

Statistical analysis
--------------------

SPSS 21.0 (IBM Corporation, Armonk, NY, USA) was employed for statistical analysis. Values were shown as the mean ± standard deviation. Student's paired or unpaired *t*-test was adopted to analyze the significance between paired and unpaired groups respectively. One-way analysis of variance test was applied to analyze the significance between groups of various differentiations of HCC. Fold change (FC) was calculated to describe the degree of difference on a log 2 scale. Statistical significance was defined at a *P*\<0.05 level.

Results
=======

Expression of miR-198 in HCC
----------------------------

The relative level of miR-198 was 1.23±0.72 in HCC tissues, remarkably lower than that in adjacent noncancerous liver tissues (2.01±0.58, *P*\<0.001) ([Table 1](#t1-ott-9-5163){ref-type="table"}, [Figure 1A](#f1-ott-9-5163){ref-type="fig"}). Furthermore, the area under curve (AUC) of miR-198 accessed by receiver operating characteristic (ROC) curve was 0.775 (95% confidence interval (CI): 0.708--0.841, *P*\<0.001) ([Figure 2A](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 1.78. The sensitivity was 66.3% and the specificity was 75.8%. However, there was no significant difference of the miR-198 level between the noncirrhotic liver (1.96±0.57) and cirrhotic liver (2.06±0.59, *t*=−0.76, *P*=0.449) ([Table 1](#t1-ott-9-5163){ref-type="table"}). And miR-198 expression was markedly downregulated in HCC (1.30±0.72) as compared to noncirrhotic liver (*t*=5.67, *P*\<0.001) and cirrhotic liver (*t*=6.25, *P*\<0.001), respectively.

Expression of miR-198 with clinicopathological parameters in HCC
----------------------------------------------------------------

Considering correlation between miR-198 expression and clinical features, several clinicopathological parameters were related to miR-198. Remarkably higher expression of miR-198 was found in the tumor with complete capsular (1.64±0.77) than in the tumor with no capsule or with tumor infiltration (0.99±0.50, *P*\<0.001) ([Figure 1B](#f1-ott-9-5163){ref-type="fig"}). MiR-198 differential expression could be found in tissue differentiation, and significant differences existed between high differentiation (1.87±0.52) and low differentiation (0.87±0.45, *P*\<0.001) ([Figure 1C](#f1-ott-9-5163){ref-type="fig"}), and similar variation was also found between moderate (1.45±0.74) and low differentiation (0.87±0.45, *P*\<0.001) ([Figure 1C](#f1-ott-9-5163){ref-type="fig"}). However, high differentiation and moderate one showed no significant difference. HCV positive patients had a noticeably lower miR-198 expression level (0.83±0.44) than negative ones (1.53±0.71, *P*\<0.001) ([Figure 1D](#f1-ott-9-5163){ref-type="fig"}). In tumor without metastasis, higher miR-198 expression (1.49±0.73) was observed compared with that with metastasis (1.12 ± 0.66, *P*=0.010) ([Figure 2E](#f2-ott-9-5163){ref-type="fig"}). Expression of miR-198 was higher in patients with single tumor node (1.47±0.76) than in those with multitumor nodes (1.08±0.61, *P*=0.008) ([Figure 1F](#f1-ott-9-5163){ref-type="fig"}). As for clinical tumor node metastasis (TNM) stage, miR-198 expression in early stages (I and II, 1.60±0.72) was higher than that in advanced stages (III and IV, 1.21±0.69, *P*=0.021) ([Figure 1G](#f1-ott-9-5163){ref-type="fig"}). Concerning the status of vaso-invasion, expression of miR-198 was lower in positive ones (1.09±0.71) than in negative ones (1.42±0.69, *P*=0.028) ([Figure 1H](#f1-ott-9-5163){ref-type="fig"}). Simultaneously, additional Spear-man's correlation test confirmed the relationship between miR-198 expression and the following clinicopathological features: differentiation (*r*=−0.43, *P*\<0.001) and clinical TNM stage (*r*=−0.23, *P*=0.024). However, no significant differences between miR-198 expression and other clinicopathological parameters were noted, such as age, sex, tumor size, portal vein tumor embolus, hepatitis B virus, alpha fetal protein, cirrhosis, expression of other markers: nm23, p53, p21, vascular endothelial growth factor, Ki-67, or microvessel density. The detection of the expression of nm23, p53, p21, vascular endothelial growth factor, Ki-67, and CD34 to present microvessel density was carried out by the immunohistochemistry method ([Figure 3A--L](#f3-ott-9-5163){ref-type="fig"}). And hematoxylin and eosin staining images of HCC, cirrhosis, and noncirrhotic liver tissues are shown in [Figure 4](#f4-ott-9-5163){ref-type="fig"}. We also searched for the data of the expression of miR-198 in Gene Expression Omnibus datasets and brought in all the HCC-related miR-198 expression chip data to perform a meta-analysis. Standardized mean difference with 95% CIs were calculated and pooled by using STATA 12.0 (StataCorp LP, College Station, TX, USA). Six microarray datasets with miR-198 expression level were employed. But the results obtained by a random-effects model showed no statistical significance (*P*\>0.05) between the expression of miR-198 in HCC and noncancer tissues (data not shown). So, the more expanded sample size will be needed for the validation of miR-198 expression in the future.

ROC analysis for miR-198 expression in HCC
------------------------------------------

ROC curve was also performed to identify the predictive value of miR-198 level in HCC patients for clinicopathological features. The AUC to discriminate HCC from adjacent noncancerous liver accessed by ROC curve was 0.775 (95% CI: 0.708\~0.841, *P*\<0.001) ([Figure 2A](#f2-ott-9-5163){ref-type="fig"}). The cut-off value for miR-198 was 1.78. The sensitivity was 66.3% and the specificity was 75.8%. The AUC to judge the capsule and tumor infiltration was 0.748 (95% CI: 0.649\~0.846, *P*\<0.001) ([Figure 2B](#f2-ott-9-5163){ref-type="fig"}). The cut-off value for miR-198 was 1.73. The sensitivity and specificity were 48.9% and 96%, respectively. The AUC to judge the HCV infected was 0.794 (95% CI: 0.702\~0.886, *P*\<0.001) ([Figure 2C](#f2-ott-9-5163){ref-type="fig"}). The cut-off value for miRNA-198 was 1.12. The sensitivity and specificity were 73% and 81.2%, respectively. The AUC to evaluate without tumor metastasis was 0.652 (95% CI: 0.542--0.761, *P*=0.011) ([Figure 2D](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 0.62. The sensitivity and specificity were 93.5% and 34.7%, respectively. The AUC to predict single tumor node was 0.647 (95% CI: 0.537--0.757, *P*=0.014) ([Figure 2E](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 1.22. The sensitivity and specificity were 59.6% and 65.1%, respectively. The AUC to estimate TNM stage was 0.658 (95% CI: 0.533--0.784, *P*=0.025) ([Figure 2F](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 1.365. The sensitivity and specificity were 59.1% and 67.1%, respectively. The AUC to predict vaso-invasion was 0.645 (95% CI: 0.526--0.763, *P*=0.018) ([Figure 2G](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 0.935. The sensitivity and specificity were 76.3% and 50%, respectively. The sensitivity and specificity were 73% and 81.2%, respectively ([Figure 2B](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 1.73. The sensitivity and specificity were 48.9% and 96%, respectively. The AUC in HCV negative patients was 0.794 (95% CI: 0.702--0.886, *P*\<0.001) ([Figure 2C](#f2-ott-9-5163){ref-type="fig"}). The cutoff value for miR-198 was 1.12. The sensitivity and specificity were 73% and 81.2%, respectively.

Role of miR-198 on recurrence of HCC patients
---------------------------------------------

We further studied the value of miR-198 on patient recurrence. Of the 95 patients studied, 70 had the complete follow-up data: 34 on low miR-198 level (lower than the median level of 1.2000) and 36 on high miR-198 level. There was no significant difference of recurrence between low miR-198 expression group and the high group (*P*=0.542).

Potential targets of miR-198 in HCC
-----------------------------------

To get predicted targets of miR-198, we conducted the prediction process online via 14 computational algorithms mentioned above, and attained a total number of 16,381 mRNAs after excluding duplications generated from the prediction process, and subsequently in order to increase reliability of our study we screened 1,048 mRNAs which were considered as more or less likely predictions. Another 37 genes validated to be the targets of miR-198 were added to our study through literature review. In addition, the abstracts or titles of 64,577 studies had been included through data and text mining tools in the process of NLP, and a total of 1,800 HCC-related genes were subsequently identified. Furthermore, we attained the potential target mRNAs of miR-198 in HCC by combining the predicted target list and genes specifically expressed in liver cancer, as shown in [Table 2](#t2-ott-9-5163){ref-type="table"}. Altogether, 127 mRNAs were selected for gene-annotation enrichment analysis and KEGG pathway annotation, which could be largely representative of the molecular mechanism of miR-198 in HCC. The flow diagram is shown in [Figure 5](#f5-ott-9-5163){ref-type="fig"}.

Gene-annotation enrichment analysis and KEGG pathway annotation
---------------------------------------------------------------

According to the functional annotation summaries with the background of Homo sapiens listed by DAVID, we gained GO term annotations and KEGG pathways of all the selected target genes of miR-198 in HCC. A modified Fisher's exact test or the EASE score was used to calculate the *P*-value. For biological process in GO results, the potential targets of miR-198 were significantly involved in the regulation of cell motion, cell migration, cell motility, regulation of cell proliferation, enzyme-linked receptor protein signaling pathway, and transmembrane receptor protein tyrosine kinase signaling pathway, and so on (*P*\<0.001, [Table 3](#t3-ott-9-5163){ref-type="table"}, [Table S1](https://www.dovepress.com/get_supplementary_file.php?f=108828.pdf)); for cellular component, these genes were most enriched in organelle lumen (n=34), membrane-enclosed lumen (n=34), nuclear lumen (n=29), plasma membrane (n=49), nucleoplasm (n=18), cytosol (n=26), ruffle (n=6), and caveola (n=5) (*P*\<0.001, [Table 3](#t3-ott-9-5163){ref-type="table"}, [Table S2](https://www.dovepress.com/get_supplementary_file.php?f=108828.pdf)); as for molecular function, the selected mRNAs were markedly involved in enzyme binding, protein domain-specific binding, and protein kinase activity, and so forth (*P*\<0.001, [Table 3](#t3-ott-9-5163){ref-type="table"}, [Table S3](https://www.dovepress.com/get_supplementary_file.php?f=108828.pdf)); and for the KEGG pathway analysis, the potential targets of miR-198 were notably associated with focal adhesion, pathways in cancer, p53 signaling pathway, and adheres junction (*P*\<0.005, [Table 4](#t4-ott-9-5163){ref-type="table"}). The overview schematic of the analysis is shown in [Table 2](#t2-ott-9-5163){ref-type="table"}, [Figures 6](#f6-ott-9-5163){ref-type="fig"} and [7](#f7-ott-9-5163){ref-type="fig"}.

Validation of some potential target gene expression based on TCGA dataset
-------------------------------------------------------------------------

Among all the significant pathways in the current study, the organelle lumen (GO: 0043233) was randomly selected. There were 34 genes involved in this pathway. We then analyzed the relative expression (on a log 2 scale) of these 34 predicted genes of miR-198 by using TCGA LIHC dataset. Eleven genes were downregulated, and they could not be real targets of miR-198 due to same trend of the expression in liver tumor ([Table 5](#t5-ott-9-5163){ref-type="table"}). And 22 among the rest 23 genes yielded significant overexpression in liver cancers as compared to that in the adjacent liver tissues (*P*\<0.05, [Table 5](#t5-ott-9-5163){ref-type="table"}). More interesting, ten among these 22 genes were extremely overexpressed in liver tumor tissues as their FC value was \>1 (*P*\<0.001, [Table 5](#t5-ott-9-5163){ref-type="table"}, [Figure 8A--J](#f8-ott-9-5163){ref-type="fig"}), such as *BIRC5, FANCD2, EGF, HMGA1, GPSM2, H2AFX, POLD1, HOXB13, HDAC4, SPDYA*.

Discussion
==========

In the present study, we found relevant lower expression of miR-198 in HCC, as compared to that in their para-noncancerous liver tissues. Downregulated miR-198 level was closely related to the disease progression of HCC. Our experiment showed that miR-198 had a close relationship with differentiation, tumor nodes, metastasis, clinical TNM stage, vaso-invasion, tumor capsular infiltration, and HCV infection. And these clinicopathological features could reflect a trend of poor prognosis. We found that the expression of miR-198 was not obviously changed in precancerous lesions of HCC, once liver tissue turned into cancerous tissue, the expression level of miR-198 was downregulated remarkably. Thus we deduce that miR-198 could have a key role in the late stage of tumorigenesis of HCC, not the period of development from normal liver to cirrhosis. Furthermore, we also performed in silico prediction for the prospective targets of miR-198 in HCC and found that miR-198 was involved in a few key pathways related to the tumorigenesis and progression of HCC. As for tissue origin, it could have been better if both normal liver tissues and adjacent noncancerous tissues had been collected in this study. Despite the adjacent noncancerous tissue from the same HCC patient, the absence of normal liver tissues is a limitation in our study.

Besides HCC, recent studies have focused on the expression of miR-198 and its regulatory roles in other diseases. Up to now, lower expression of miR-198 has been reported in lung adenocarcinoma,[@b4-ott-9-5163] pancreatic cancer,[@b20-ott-9-5163] and colorectal cancer.[@b10-ott-9-5163] However, higher expressed miR-198 has been confirmed in other malignancies such as retinoblastoma,[@b7-ott-9-5163] squamous cell carcinoma of tongue,[@b6-ott-9-5163] esophageal cancer,[@b5-ott-9-5163] pancreatic adenocarcinoma or ampullary adenocarcinoma,[@b8-ott-9-5163] prostate cancer,[@b11-ott-9-5163] and multiple myeloma.[@b9-ott-9-5163] Overexpression of miR-198 has also been found in noncancerous diseases such as severe preeclampsia,[@b21-ott-9-5163] lupus nephritis,[@b22-ott-9-5163] and human anencephaly.[@b23-ott-9-5163] In lung cancer, Yang et al reported that miR-198 could suppress proliferation and induce apoptosis by targeting fibroblast growth factor receptor 1 in vitro,[@b24-ott-9-5163] while Wu et al validated that serine hydroxymethyltransferase 1, another target of miR-198, could exert similar functions in lung adenocarcinoma.[@b25-ott-9-5163] In colorectal cancer, Wang et al demonstrated that miR-198 targeted fucosyltransferase 8 to inhibit tumor growth and metastasis.[@b10-ott-9-5163] And in pancreatic cancer, Marin-Muller et al identified miR-198 as a crucial tumor suppressor which linked a tumor network signature including mesothelin, OCT-2, pre-B-cell leukemia homeobox 1, and valosin containing protein and prognosticates poor patient outcome.[@b20-ott-9-5163] miR-198 could play versatile roles in different diseases via influencing various biological processes.

So far, several studies have been conducted on the roles of miR-198 in HCC. Varnholt et al first reported that miR-198 was downregulated in HCV-associated HCC compared to normal hepatic parenchyma in Caucasian patients,[@b12-ott-9-5163] but the study was confined to the limitation of racial difference. Later, Tan et al[@b13-ott-9-5163] identified the suppressing role of miR-198 in HGF/c-MET pathway that influenced migration and invasion of HCC cells. Then, Elfimova et al[@b14-ott-9-5163] found that miR-198 was associated with the repression of mitogenic and motogenic pathways in vitro, which could negatively regulate cell growth and migration, thus classifying miR-198 as a main tumor suppressor miRNA in HCC carcinogenesis. However, no study has been reported on the relationship between miR-198 and its corresponding clinicopathological parameters in HCC in the existing literatures. What consisted in previous studies was that the lower expression of miR-198 was confirmed in 95 HCC tissues, compared to their paired controls. The comparison between HCC and the paired noncancerous liver tissues can effectively avoid individual differences and lead to a reliable experimental result. Furthermore, in this study, we revealed the clinicopathological value of miR-198 in HCC. It was obvious that lower expression of miR-198 could be seen in HCC tissues characterized by HCV positive groups, deficient tumor capsule, tumor with metastasis, multitumor nodes, vaso-invasion positive, clinical TNM stage of III--IV, and low differentiation (compared to high differentiation and moderate differentiation separately). Evidently, lower expression of miR-198 might develop a relationship with the tumorigenesis and disease progression of HCC.

To obtain insight into the potential function of miR-198 in the process of tumorigenesis of HCC, we further focused on the function based on in silico methods. Although some studies have reported the method of miRNA targets prediction through two or three public databases online; however, from the perspective of artificial prediction, there still can be some inevitable insufficiencies in the single computational algorithm. Therefore, in this study, we used 14 computational algorithms online to predict the putative targets of miR-198, and screened the possible targets in a high probability. Moreover, to achieve potential target mRNAs especially expressed in HCC, we further narrowed down the list by performing NLP analysis in HCC. Having identified 127 mRNAs as potential targets for miR-198, we performed GO enrichment analysis and KEGG pathway annotation to further explore the regulatory function of these mRNAs in HCC. Significant results were adopted according to the *P*-value provided by DAVID.[@b20-ott-9-5163] We observed that these mRNAs were most enriched in organelle lumen, membrane-enclosed lumen, nuclear lumen, and plasma membrane, which indicated a potential membrane-associated metabolism regulated by these target genes. Besides, for biological process, we found these targets were significantly involved in regulation of cell proliferation, cell migration, cell motion, cell motility, and localization of cell, which may contribute to the clinicopathological manifestation of multiple tumor nodes, vaso-invasion, metastasis, and capsular formation, respectively. As for molecular function, the selected mRNAs were significantly involved in enzyme binding, protein domain-specific binding, and protein kinase activity, which showed high tendency of cellular invasion. Furthermore, in KEGG pathway analysis, we found that the targeted mRNAs were most associated with focal adhesion, pathways in cancer, p53 signaling pathway, and adheres junction, which indicated that the potential miR-198 targets may participate in tumor-related intercellular signaling molecules exchange and signal transduction, thus contributing to the stepwise development of tumorigenesis in HCC.

To better explore the possibility of the target candidates from simple prediction, we further inspected liver data on TCGA dataset and confirmed the overexpression of 23 of 34 genes described in the organelle lumen (GO: 0043233), which was the most significant GO term for cellular component. Especially, ten genes were dramatically upregulated in liver tumor tissues, giving a FC of \>1. These genes may have more possibility to be the real targets of miR-198 in HCC due to their noteworthy overexpression in cancer tissues. Of course, the results need to be further confirmed with other experiments.

Conclusion
==========

In this study, we confirmed the lower expression of miR-198 in HCC by using RT-qPCR on paraffin-embedded tissues; potential targets and pathways of miR-198 were achieved through bioinformatics methods, which further clarified the potential role of miR-198 in the processes of hepatocellular carcinogenesis. Additionally, we provided guidelines for clinical reference and scientific research in the future. In conclusion, miR-198 might play essential regulatory roles via different target genes and relevant pathways in the development of HCC. Further investigation of the molecular mechanisms of miR-198 is needed to be explored in malignant phenotype of HCC.
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![miR-198 expression in HCC tissue.\
**Notes:** Quantitative real-time PCR was performed to detect the expression of miR-198 in HCC tissue and adjacent noncancerous hepatic tissue. \*\*\* *P*\<0.001, \*\* *P*\<0.01, \* *P*\<0.05. (**A**) Tissue, (**B**) tumor capsular infiltration, (**C**) differentiation: high differentiation (1.8650±0.5217) is higher expressed than low differentiation (0.8652±0.4475, *P*\<0.001), moderate differentiation (1.4495±0.7414) is higher expressed than low differentiation (0.8652±0.4475, *P*\<0.001). (**D**) HCV infected, (**E**) metastasis, (**F**) tumor nodes, (**G**) clinical TNM stage, (**H**) vaso-invasion.\
**Abbreviations:** HCC, hepatocellular carcinoma; HCV, hepatitis C virus; miR-198, microRNA-198; PCR, polymerase chain reaction; TNM, tumor node metastasis.](ott-9-5163Fig1){#f1-ott-9-5163}

###### 

Significance of miR-198 with different parameters in HCC with the ROC curve analysis.

**Notes:** (**A**) Discrimination of HCC from adjacent noncancerous liver, (**B**) evaluating capsular infiltration, (**C**) HCV infected, (**D**) metastasis, (**E**) tumor nodes, (**F**) TNM stage, (**G**) vaso-invasion.

**Abbreviations:** AUC, area under the curve; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; miR-198, microRNA-198; ROC, receiver operating characteristic; TNM, tumor node metastasis.
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###### 

Immunohistochemistry images of HCC under microscope (×40, ×100, and ×400).

**Notes: (A)** nm23 positive; (**B**) nm23 negative; (**C**) p21 positive; (**D**) p21 negative; (**E**) p53 positive; (**F**) p53 negative; (**G**) VEGF positive; (**H**) VEGF negative; (**I**) Ki-67 LI high; (**J**) Ki-67 LI low; (**K**) MVD high; (**L**) MVD low.

**Abbreviations:** HCC, hepatocellular carcinoma; MVD, microvessel density; VEGF, vascular endothelial growth factor.
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![HE staining images of HCC (**A**), cirrhosis (**B**), noncirrhotic liver tissue (**C**), under microscope (×40, ×100, ×400).\
**Abbreviations:** HCC, hepatocellular carcinoma; HE, hematoxylin and eosin.](ott-9-5163Fig4){#f4-ott-9-5163}

![The flow diagram of the bioinformatics study for miR-198 in HCC.\
**Abbreviations:** GO, Gene Ontology; HCC, hepatocellular carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; mRNA, messenger RNA; miR-198, microRNA-198; NLP, natural language processing.](ott-9-5163Fig5){#f5-ott-9-5163}

![The significantly enriched annotation of GO categories and KEGG pathway of the potential mRNAs targeted by miR-198 in HCC.\
**Abbreviations:** GO, Gene Ontology; HCC, hepatocellular carcinoma; KEGG, Kyoto Encyclopedia of Genes and Genomes; mRNA, messenger RNA; miR-198, microRNA-198.](ott-9-5163Fig6){#f6-ott-9-5163}

![Enrichment map of the potential mRNAs targeted by miR-198 in HCC.\
**Notes:** The red circle represents GO terms enriched based on potential mRNAs targeted by miR-198 in HCC. The green line is representative of the same mRNAs that belong to both ends of enriched GO terms.\
**Abbreviations:** GO, Gene Ontology; HCC, hepatocellular carcinoma; mRNA, messenger RNA; miR-198, microRNA-198.](ott-9-5163Fig7){#f7-ott-9-5163}

###### 

Expressions of the top ten genes with most significant fold changes from organelle lumen pathway in liver tumor based on TCGA dataset.

**Notes:** The TCGA RNAseq profiles of LIHC were extracted to explore the relative expressions of ten selected genes from organelle lumen pathway in liver tumor tissue and adjacent liver tissue (on a log 2 scale). \*\*\* *P*\<0.001. (**A**) BIRC5, (**B**) FANCD2, (**C**) EGF, (**D**) HMGA1, (**E**) GPSM2, (**F**) H2AFX, (**G**) POLD1, (**H**) HOXB13, (**I**) HDAC4, (**J**) SPDYA.

**Abbreviations:** RNAseq, RNA sequencing; TCGA, The Cancer Genome Atlas; LIHC, Liver Hepatocellular Carcinoma.
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###### 

Relationship between the expression of miR-198 and clinicopathological features in HCC

  Clinicopathological feature    n    miR-198 relevant expression (2^−ΔCq^)           
  ------------------------------ ---- --------------------------------------- ------- ---------------------------------------------------------------------------------------------------
  Tissue                                                                              
   Adjacent noncancerous liver   95   2.01±0.58                               7.53    \<0.001[\*\*\*](#tfn3-ott-9-5163){ref-type="table-fn"},[a](#tfn4-ott-9-5163){ref-type="table-fn"}
   Noncirrhotic liver            50   1.96±0.57                               −0.76   0.449[b](#tfn5-ott-9-5163){ref-type="table-fn"}
   Cirrhotic liver               45   2.06±0.59                               5.67    \<0.001[\*\*\*](#tfn3-ott-9-5163){ref-type="table-fn"},[c](#tfn6-ott-9-5163){ref-type="table-fn"}
   HCC                           95   1.30±0.72                               6.25    \<0.001[\*\*\*](#tfn3-ott-9-5163){ref-type="table-fn"},[d](#tfn7-ott-9-5163){ref-type="table-fn"}
  Age, years                                                                          
   ≥50                           46   1.42±0.74                               1.66    0.10
   \<50                          49   1.18±0.68                                       
  Sex                                                                                 
   Male                          75   1.30±0.69                               0.04    0.97
   Female                        20   1.29±0.83                                       
  Differentiation                                                                     
   High                          6    1.87±0.52                               10.20   \<0.001[\*\*\*](#tfn3-ott-9-5163){ref-type="table-fn"},[e](#tfn8-ott-9-5163){ref-type="table-fn"}
   Moderate                      60   1.45±0.74                                       
   Low                           29   0.87±0.45                                       
  Size (cm)                                                                           
   \<5                           18   1.48±0.72                               0.99    0.33
   ≥5                            77   1.26±0.72                                       
  Tumor nodes                                                                         
   Single                        52   1.47±0.76                               2.72    0.008[\*\*](#tfn2-ott-9-5163){ref-type="table-fn"}
   Multi                         43   1.08±0.61                                       
  Metastasis                                                                          
   Without metastasis            46   1.49±0.73                               2.62    0.01[\*](#tfn1-ott-9-5163){ref-type="table-fn"}
   With metastasis               49   1.12±0.66                                       
  Clinical TNM stage                                                                  
   I--II                         22   1.60±0.72                               2.34    0.021[\*](#tfn1-ott-9-5163){ref-type="table-fn"}
   III--IV                       73   1.21±0.69                                       
  Portal vein tumor embolus                                                           
   −                             63   1.35±0.71                               1.03    0.31
   +                             32   1.19±0.72                                       
  Vaso-invasion                                                                       
   −                             59   1.42±0.69                               2.23    0.028[\*](#tfn1-ott-9-5163){ref-type="table-fn"}
   +                             36   1.09±0.71                                       
  Tumor capsular infiltration                                                         
   With complete capsule         45   1.64±0.77                               4.92    \<0.001[\*\*\*](#tfn3-ott-9-5163){ref-type="table-fn"}
   No capsule infiltration       50   0.99±0.50                                       
  HCV                                                                                 
   −                             63   1.53±0.71                               5.89    \<0.001[\*\*\*](#tfn3-ott-9-5163){ref-type="table-fn"}
   +                             32   0.83±0.44                                       
  HBV                                                                                 
   −                             17   1.42±0.78                               0.77    0.44
   +                             78   1.27±0.70                                       
  AFP                                                                                 
   −                             41   1.40±0.79                               1.36    0.18
   +                             38   1.17±0.71                                       
  Cirrhosis                                                                           
   −                             50   1.21±0.71                               −1.30   0.20
   +                             45   1.40±0.72                                       
  nm23                                                                                
   −                             20   1.29±0.67                               −0.07   0.95
   +                             75   1.30±0.73                                       
  P53                                                                                 
   −                             40   1.29±0.75                               −0.04   0.97
   +                             55   1.30±0.69                                       
  P21                                                                                 
   −                             62   1.34±0.78                               0.81    0.42
   +                             33   1.22±0.58                                       
  VEGF                                                                                
   −                             25   1.15±0.65                               −1.21   0.23
   +                             70   1.35±0.73                                       
  Ki-67LI                                                                             
   Low                           47   1.40±0.72                               1.37    0.18
   High                          48   1.20±0.70                                       
  MVD                                                                                 
   Low                           47   1.24±0.67                               −0.73   0.47
   High                          48   1.35±0.76                                       

**Notes:**

*P*\<0.05,

*P*\<0.01,

*P*\<0.001.

Adjacent noncancerous liver (including liver with and without cirrhosis) vs HCC.

Noncirrhotic liver vs cirrhotic liver.

Noncirrhotic liver vs HCC.

Cirrhotic liver vs HCC.

Differentiation group pairwise comparison: high vs low differentiation (*t*=4.851, *P*\<0.001) and moderate vs low (*t*=4.610, *P*\<0.001) have significant differences, high vs moderate (*t*=1.336, *P*=0.186) has no difference.

**Abbreviations:** AFP, alpha fetal protein; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; HCV, hepatitis C virus; miR-198, microRNA-198; MVD, microvessel density; SD, standard deviation; TNM, tumor node metastasis; VEGF, vascular endothelial growth factor.

###### 

Potential target mRNAs of miR-198 in HCC

  --------- ---------- -------- ---------- --------- -------- ---------- ----------
  VCP       CDH11      CCND2    PAK6       ADARB1    DGCR8    MSI2       SERPINF2
  HMGA1     DENND2D    CDK6     PAPSS1     APBA2     DKK3     MYB        SHOX2
  PTEN      HOXA1      CSF1     PER2       ARHGEF9   ELAVL1   NLK        SMAD2
  CDK4      LARP1      CTBP2    POLR2E     BIRC5     FANCD2   NOVA1      SP1
  FUT8      MAPRE1     DDR1     PPP2R5E    BMF       FOXJ1    NTRK3      SPRY2
  MET       NCOR2      EGF      SERPINA5   BTG2      GPSM2    PAFAH1B1   SRC
  SLC2A1    NEK8       FASN     SETD4      BVES      H2AFX    PCDH9      TLN1
  CNR1      OGT        FRS2     SETDB1     CACNA1C   HDAC4    PEA15      TNFRSF18
  MSR1      PDCD1LG2   FTCD     SPTBN1     CAPN2     HDGF     PEG10      TNK2
  PPP1R9B   PTPN1      HOXB13   STK17B     CBL       HDLBP    PLAU       TNRC6B
  ADAM12    RAD52      IDS      TFCP2      CD4       HFE      POLD1      TRIM3
  ARHGAP1   SORT1      ITGA5    TLN2       CDKN2B    INPPL1   PPARA      YWHAG
  ASPH      THBS1      MAP2K7   TNFRSF8    CNTN2     ISX      PSD3       ZEB2
  BAG3      AMFR       MLL2     TPM3       CTGF      KRT14    PVR        SLC16A7
  BCL2L1    BMPR1A     MST1R    ULK1       CYCS      MPZL1    PVRL2      SPDYA
  CBS       CAPN9      MTSS1    WHSC1      DACH1     MSI1     RPL41      
  --------- ---------- -------- ---------- --------- -------- ---------- ----------

**Abbreviations:** HCC, hepatocellular carcinoma; miR-198, microRNA-198; mRNA, messenger RNA.

###### 

GO functional annotation for most significantly related targets of miR-198

  GO ID                    GO term                                                            Count (%)   *P*-value   Gene symbol
  ------------------------ ------------------------------------------------------------------ ----------- ----------- -----------------------------------------------------------------
  **Biological process**                                                                                              
  GO:0007167               Enzyme-linked receptor protein signaling pathway                   20 (1.3)    1.82E-10    MTSS1, MPZL1, FUT8, NLK, CBL, MET, SMAD2, PTEN, SRC, etc
  GO:0007169               Transmembrane receptor protein tyrosine kinase signaling pathway   15 (1.0)    1.23E-08    MTSS1, MPZL1, CBL, MET, PTEN, SRC, NTRK3, DDR1, CTGF, etc
  GO:0006928               Cell motion                                                        20 (1.3)    4.06E-08    PVR, MTSS1, TLN1, FUT8, FOXJ1, MET, ZEB2, PTEN, SRC, etc
  GO:0016477               Cell migration                                                     14 (0.9)    1.10E-06    PVR, FUT8, FOXJ1, MET, ZEB2, PTEN, SRC, ULK1, ITGA5, etc
  GO:0042127               Regulation of cell proliferation                                   23 (1.5)    1.59E-06    CTBP2, FOXJ1, CSF1, TNFRSF8, CDK6, SMAD2, BCL2L1, CDK4, etc
  GO:0051674               Localization of cell                                               14 (0.9)    3.59E-06    PVR, FUT8, FOXJ1, MET, ZEB2, PTEN, SRC, ULK1, ITGA5, etc
  GO:0048870               Cell motility                                                      14 (0.9)    3.59E-06    PVR, FUT8, FOXJ1, MET, ZEB2, PTEN, SRC, ULK1, ITGA5, etc
  GO:0042325               Regulation of phosphorylation                                      17 (1.1)    3.90E-06    CSF1, MET, ZEB2, PTEN, SPDYA, PPP1R9B, SPRY2, YWHAG, etc
  GO:0051174               Regulation of phosphorus metabolic process                         17 (1.1)    6.48E-06    CSF1, MET, ZEB2, PTEN, SPDYA, PPP1R9B, SPRY2, YWHAG, etc
  GO:0019220               Regulation of phosphate metabolic process                          17 (1.1)    6.48E-06    CSF1, MET, ZEB2, PTEN, SPDYA, PPP1R9B, SPRY2, YWHAG, etc
  **Cellular component**                                                                                              
  GO:0043233               Organelle lumen                                                    34 (2.2)    5.11E-06    POLR2E, HOXB13, DGCR8, GPSM2, CD4, H2AFX, OGT, THBS1, etc
  GO:0031974               Membrane-enclosed lumen                                            34 (2.2)    7.82E-06    POLR2E, HOXB13, DGCR8, GPSM2, CD4, H2AFX, OGT, THBS1, etc
  GO:0031981               Nuclear lumen                                                      29 (1.9)    1.07E-05    POLR2E, HOXB13, DGCR8, GPSM2, H2AFX, OGT, MYB, NOVA1, etc
  GO:0005829               Cytosol                                                            26 (1.7)    5.67E-05    TLN1, INPPL1, CBL, CYCS, BIRC5, SMAD2, BCL2L1, ARHGEF9, etc
  GO:0070013               Intracellular organelle lumen                                      31 (2.0)    6.56E-05    POLR2E, HOXB13, DGCR8, GPSM2, CD4, H2AFX, OGT, MYB, etc
  GO:0001726               Ruffle                                                             6 (0.4)     2.19E-04    MTSS1, TLN1, TLN2, ITGA5, ARHGAP1, CDK6
  GO:0005886               Plasma membrane                                                    49 (3.1)    3.18E-04    PVR, HDLBP, TLN1, MPZL1, MSR1, TLN2, CSF1, HFE, TNFRSF8, etc
  GO:0005654               Nucleoplasm                                                        18 (1.2)    8.06E-04    CTBP2, ADARB1, POLR2E, HOXB13, SMAD2, DACH1, RAD52, CDK4, etc
  GO:0005901               Caveola                                                            5 (0.3)     8.60E-04    CBL, SLC2A1, CACNA1C, SRC, BMPR1A
  GO:0031252               Cell leading edge                                                  7 (0.4)     9.53E-04    MTSS1, TLN1, TLN2, ITGA5, ARHGAP1, CDK6, PAFAH1B1
  **Molecular function**                                                                                              
  GO:0019899               Enzyme binding                                                     21 (1.3)    1.55E-08    NLK, BIRC5, SMAD2, HMGA1, SPDYA, HDAC4, PPP1R9B, etc
  GO:0019904               Protein domain-specific binding                                    13 (0.8)    2.54E-05    PPARA, MTSS1, TLN1, YWHAG, FUT8, VCP, INPPL1, NLK, etc
  GO:0004672               Protein kinase activity                                            16 (1.0)    1.94E-04    PAK6, NTRK3, DDR1, POLR2E, ULK1, NLK, MET, NEK8, etc
  GO:0017124               SH3 domain binding                                                 6 (0.4)     1.38E-03    MTSS1, FUT8, INPPL1, CBL, ARHGAP1, ADAM12
  GO:0004713               Protein tyrosine kinase activity                                   7 (0.4)     2.99E-03    NTRK3, DDR1, MET, TNK2, MST1R, MAP2K7, SRC
  GO:0019900               Kinase binding                                                     7 (0.4)     4.33E-03    SPDYA, YWHAG, CDKN2B, CCND2, SLC2A1, CD4, MAP2K7
  GO:0032403               Protein complex binding                                            7 (0.4)     6.70E-03    ULK1, ITGA5, CTGF, SPTBN1, PTPN1, THBS1, FRS2
  GO:0004857               Enzyme inhibitor activity                                          8 (0.5)     8.43E-03    PPP1R9B, YWHAG, CDKN2B, SERPINF2, SERPINA5, BIRC5, BCL2L1, TNK2
  GO:0019901               Protein kinase binding                                             6 (0.4)     8.53E-03    SPDYA, YWHAG, CDKN2B, CCND2, CD4, MAP2K7

**Abbreviations:** GO, Gene Ontology; miR-198, microRNA-198.

###### 

KEGG pathway enrichment analysis of miR-198 target genes

  KEGG ID    KEGG term                    Count (%)   *P*-value   Gene symbol
  ---------- ---------------------------- ----------- ----------- --------------------------------------------------------------
  hsa04510   Focal adhesion               12 (0.8)    5.93E-05    SPDYA, PAK6, TLN1, CCND2, TLN2, ITGA5, MET, EGF, CAPN2, etc
  hsa05200   Pathways in cancer           14 (0.9)    3.25E-04    CTBP2, CBL, MET, CYCS, CDK6, BIRC5, SMAD2, BCL2L1, CDK4, etc
  hsa04115   p53 signaling pathway        6 (0.4)     2.00E-03    CCND2, CYCS, CDK6, CDK4, THBS1, PTEN
  hsa04520   Adherens junction            6 (0.4)     3.46E-03    NLK, MET, PVRL2, SMAD2, PTPN1, SRC
  hsa05222   Small cell lung cancer       6 (0.4)     5.03E-03    CDKN2B, CYCS, CDK6, BCL2L1, CDK4, PTEN
  hsa05218   Melanoma                     5 (0.3)     1.45E-02    MET, CDK6, EGF, CDK4, PTEN
  hsa05212   Pancreatic cancer            5 (0.3)     1.52E-02    CDK6, SMAD2, BCL2L1, EGF, CDK4
  hsa05220   Chronic myeloid leukemia     5 (0.3)     1.75E-02    CTBP2, CBL, CDK6, BCL2L1, CDK4
  hsa04110   Cell cycle                   6 (0.4)     2.52E-02    YWHAG, CDKN2B, CCND2, CDK6, SMAD2, CDK4
  hsa04350   TGF-beta signaling pathway   5 (0.3)     2.84E-02    CDKN2B, SP1, SMAD2, THBS1, BMPR1A
  hsa04012   ErbB signaling pathway       5 (0.3)     2.84E-02    PAK6, CBL, EGF, MAP2K7, SRC
  hsa04514   CAMs                         6 (0.4)     3.09E-02    PVR, MPZL1, PVRL2, CNTN2, CD4, PDCD1LG2

**Abbreviations:** CAMs, cell adhesion molecules; KEGG, Kyoto Encyclopedia of Genes and Genomes; miR-198, microRNA-198.

###### 

Expressions of 34 genes based on TCGA dataset (369 liver tumor tissues and 50 adjacent nontumor tissues)

  Gene name   Liver tumor (Mean ± SD)   Adjacent liver (Mean ± SD)   *t*      *P*-value   FC
  ----------- ------------------------- ---------------------------- -------- ----------- -------
  BIRC5       7.34±1.78                 2.89±1.47                    16.87    4.77E-49    4.45
  FANCD2      7.05±1.38                 4.59±0.91                    16.67    3.16E-28    2.46
  EGF         1.91±2.84                 0.28±0.65                    9.34     1.45E-18    1.63
  HMGA1       10.53±1.20                8.98±0.71                    13.15    6.28E-23    1.55
  GPSM2       7.06±1.09                 5.58±0.63                    14.08    5.19E-25    1.48
  H2AFX       9.34±1.00                 8.06±0.49                    14.84    2.08E-28    1.29
  POLD1       9.19±0.79                 7.92±0.43                    17.33    4.57E-32    1.27
  HOXB13      1.31±2.46                 0.05±0.51                    8.61     2.30E-16    1.27
  HDAC4       7.85±0.78                 6.81±0.56                    11.60    1.39E-18    1.04
  SPDYA       3.09±1.03                 2.06±0.90                    6.73     5.75E-11    1.03
  SETDB1      9.90±0.59                 8.93±0.30                    18.55    1.12E-35    0.97
  MYB         2.97±1.81                 2.04±1.54                    3.91     2.17E-04    0.93
  CDK4        10.96±0.69                10.27±0.25                   13.79    5.06E-30    0.69
  OGT         10.80±0.63                10.13±0.43                   9.63     4.99E-15    0.67
  NCOR2       11.01±0.61                10.45±0.37                   9.28     8.65E-15    0.57
  MLL2        10.06±0.74                9.53±0.57                    5.92     9.52E-08    0.53
  RAD52       6.46±0.71                 6.00±0.59                    4.37     1.58E-05    0.46
  SMAD2       10.09±0.47                9.74±0.22                    8.63     3.09E-14    0.35
  CYCS        11.63±0.73                11.33±0.37                   4.52     1.61E-05    0.29
  NLK         8.92±0.46                 8.67±0.29                    5.26     1.08E-06    0.25
  VCP         12.96±0.40                12.76±0.23                   5.16     1.44E-06    0.20
  DGCR8       9.23±0.44                 9.04±0.32                    3.65     4.70E-04    0.18
  SP1         10.63±0.44                10.57±0.27                   1.36     1.78E-01    0.06
  POLR2E      12.08±0.54                12.16±0.39                   −1.28    2.05E-01    −0.08
  PPP1R9B     9.60±0.86                 9.70±0.48                    −1.24    2.18E-01    −0.10
  ADARB1      7.93±0.79                 8.04±0.35                    −1.56    1.20E-01    −0.10
  NOVA1       3.59±2.45                 3.77±0.79                    −1.08    2.82E-01    −0.18
  SPTBN1      13.44±0.66                13.66±0.46                   −2.97    3.97E-03    −0.22
  CTBP2       7.45±1.27                 7.82±0.47                    −3.88    1.50E-04    −0.36
  CBS         11.90±1.64                13.49±0.42                   −15.18   9.33E-39    −1.58
  SERPINF2    14.40±1.82                16.14±0.35                   −16.27   1.39E-45    −1.74
  THBS1       10.55±1.75                12.68±1.11                   −11.75   1.33E-19    −2.13
  CD4         9.89±1.23                 12.06±0.70                   −18.55   1.13E-33    −2.18
  DACH1       2.64±1.61                 6.01±0.65                    −27.11   9.98E-60    −3.37

**Abbreviations:** FC, fold change; SD, standard deviation; TCGA, The Cancer Genome Atlas.

[^1]: These authors contributed equally to this work
